ChiCTR1900028587 版本V1.0 版本创建时间2020/03/03 11:09:39 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900028587 

最近更新日期:

Date of Last Refreshed on:

2019-12-28 21:45:48 

注册时间:

Date of Registration:

2019-12-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

邢纪斌医师:该研究的伦理审批文件未上传,请尽快上传并填写伦理审批日期。 右旋美托咪定复合B超引导下神经阻滞治疗带状疱疹后神经痛:一项前瞻、对照的临床研究

Public title:

The effect of Dexmedetomidine combined with b-ultrasound-guided nerve block in postherpes neuralgia: a prospective, randomized controlled clinical study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

右旋美托咪定复合B超引导下神经阻滞治疗带状疱疹后神经痛:一项前瞻、对照的临床研究

Scientific title:

The effect of Dexmedetomidine combined with b-ultrasound-guided nerve block in postherpes neuralgia: a prospective, randomized controlled clinical study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

邢纪斌 

研究负责人:

邢纪斌 

Applicant:

Xing Jibin 

Study leader:

Xing Jibin 

申请注册联系人电话:

Applicant telephone:

+86 13512728239

研究负责人电话:

Study leader's telephone:

+86 13512728239

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

beenjoy@qq.com

研究负责人电子邮件:

Study leader's E-mail:

beenjoy@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广州市天河区天河路600号

研究负责人通讯地址:

广州市天河区天河路600号

Applicant address:

600 Tianhe Road, Tianhe District, Guangzhou, Guangdong

Study leader's address:

600 Tianhe Road, Tianhe District, Guangzhou, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中山大学附属第三医院

Applicant's institution:

The Third Affiliated Hospital of Sun Yat-Sen University

研究负责人所在单位:

中山大学附属第三医院

Affiliation of the Leader:

The Third Affiliated Hospital of Sun Yat-Sen University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

中大附三医伦[2019]02-482-01

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

中山大学附属第三医院医学伦理委员会

Name of the ethic committee:

The Ethics Committee of the Third Affiliated Hospital of Sun Yat-Sen University

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

黄桂珍

Contact Name of the ethic committee:

Guizhen Huang

伦理委员会联系地址:

广州市天河区天河路600号

Contact Address of the ethic committee:

600 Tianhe Road, Tianhe District, Guangzhou, Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中山大学附属第三医院

Primary sponsor:

The Third Affiliated Hospital of Sun Yat-Sen University

研究实施负责(组长)单位地址:

广州市天河区天河路600号

Primary sponsor's address:

600 Tianhe Road, Tianhe District, Guangzhou, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

中山大学附属第三医院

具体地址:

天河区天河路600号

Institution
hospital:

广州市天河区天河路600号

Address:

600 Tianhe Road, Tianhe District

经费或物资来源:

自筹

Source(s) of funding:

Self-raised

Target disease:

Pain

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本课题拟设计一项前瞻性临床研究,探讨应用DEX复合神经阻滞提高PHN治疗效果的可能性。  

Objectives of Study:

This project intends to design a prospective clinical study to explore the possibility of using DEX combined nerve block to improve the therapeutic effect of PHN.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

a. 确诊带状疱疹后肋间神经痛而未行神经阻滞治疗的患者;
b. 年龄18-80岁;
c. 神经阻滞区域无畸形、无严重感染或肿瘤;
d. 愿意接受研究并签署研究同意书。

Inclusion criteria

A. Patients diagnosed with post-herpes zoster intercostal neuralgia without nerve block therapy;
B. Aged 18-80 years;
C. There was no deformity or serious infection in the spine and ribs in the nerve block area;
D. Willing to accept the study and sign the study consent form.

排除标准:

a. ASA分级≥3级,如:合并严重的心脑血管疾病、未控制的糖尿病等;
b. 精神异常和神经病变导致感觉异常的患者;
c. 有研究药物过敏史的患者;
d. 凝血功能严重异常的患者。

Exclusion criteria:

A. ASA grade >=3, such as severe cardiovascular and cerebrovascular diseases combined with uncontrolled diabetes, etc.;
B. patients with psychiatric and neuropathic disorders that cause paresthesia;
C. Patients with a history of drug allergy;
D. Patients with severe abnormal coagulation function.

研究实施时间:

Study execute time:

From 2019-12-30 00:00:00 To 2021-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-12-31 00:00:00 To 2020-05-05 00:00:00  

干预措施:

Interventions:

组别:

常规治疗组

样本量:

99

Group:

Regular treatment

Sample size:

干预措施:

常规治疗

干预措施代码:

Intervention:

Regular treatment

Intervention code:

组别:

右旋美托嘧啶组

样本量:

99

Group:

DEX

Sample size:

干预措施:

B超引导下神经阻滞+dex 1.0 ug/Kg

干预措施代码:

Intervention:

B-ultrasound guided nerve block +dex 1.0ug /Kg

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China 

Province:

Guangdong 

City:

Guangzhou 

单位(医院):

中山大学附属第三医院 

单位级别:

三甲 

Institution
hospital:

The Third Affiliated Hospital of Sun Yat-Sen University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

视觉模拟量表

指标类型:

主要指标

Outcome:

Visual Analogotls Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

红外成像图

指标类型:

次要指标

Outcome:

Infrared image

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

痛阈

指标类型:

主要指标

Outcome:

threshold of pain

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

满意度评分

指标类型:

主要指标

Outcome:

satisfaction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血药浓度

指标类型:

主要指标

Outcome:

plasma concentration

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血糖

指标类型:

主要指标

Outcome:

blood glucose

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心理学评分

指标类型:

次要指标

Outcome:

Psychological score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血清

组织:

Sample Name:

serum

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

计算机随机数法

Randomization Procedure (please state who generates the random number sequence and by what method):

Computer random number

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

受试者随机分组并且不告知所在的组别或所接受的干预措施;各组得治疗药物均为无色无味液体,由另外一位研究者配制并标注不重复的数字编号;对研究的资料收集者、分析者设盲。

Blinding:

Blind method for subjects, data collectors and analysts.

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

http://www.zssy.com.cn/#

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.zssy.com.cn/#

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

http://www.zssy.com.cn/#

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

http://www.zssy.com.cn/#

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-12-28 21:45:48